Stan­ford team preps first hu­man CRISPR study for sick­le cell dis­ease cure; Shkre­li fin­gers his for­mer at­tor­neys

Stan­ford sci­en­tists say they have been able to use CRISPR gene edit­ing tech to cor­rect a faulty gene that trig­gers sick­le cell dis­ease. And now the team wants to take their work in­to the first hu­man stud­ies for the dis­ease. ”What we’ve fi­nal­ly shown is that we can do it. It’s not just on the chalk­board,” se­nior au­thor Matthew Por­teus tells Reuters.

My­lan and Bio­con have sub­mit­ted the lat­est biosim­i­lar for an FDA re­view. This ap­pli­ca­tion is for a knock­off of Her­ceptin for HER-2 pos­i­tive breast and gas­tric can­cers. Bio­con al­ready won an ap­proval in In­dia, mark­ing the first ap­proved biosim­i­lar of Her­ceptin. Mean­while, the an­a­lysts at Re­search and Mar­kets re­cent­ly count­ed four in late-stage de­vel­op­ment that ap­peared to be head­ed to the mar­ket in com­ing years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER